PRESS RELEASE
Apr 01, 2025
BioStem Technologies Announces Extension to File 2024 Annual Report with OTC
Mar 31, 2025
BioStem Announces Notice of Allowance for Two U.S. Patent Applications
Mar 27, 2025
BioStem Technologies to Present at the 24th Annual Needham Virtual Healthcare Conference
Mar 17, 2025
BioStem Technologies: Building On Advanced Wound Care Needs
Feb 24, 2025
BioStem Receives Institutional Review Board (IRB) Approval to Advance Clinical Trial Demonstrating the Therapeutic Benefits of BioREtain® Technology in Treating Venous Leg Ulcers
Jan 13, 2025
BioStem Technologies Announces Record Preliminary Fourth Quarter Net Revenue of $102.9 Million, with Full-Year 2024 Net Revenue Expected to Reach $301.8 Million
Jan 08, 2025
BioStem Technologies Launches Clinical Trial to Demonstrate the Therapeutic Benefits of its BioREtain® Technology in Treating Diabetic Foot Ulcers Using Vendaje®
Jan 02, 2025
BioStem Technologies CEO to Present at Biotech Showcase 2025
Nov 25, 2024
BioStem Announces Notice of Allowance for U.S. Patent Application for Sterile Human Placental Allografts
Nov 20, 2024
BioStem Technologies Signs Letter of Intent to Acquire Wound Care Products and Technologies from ProgenaCare Global